Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Rating of “Reduce” from Brokerages

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been given an average rating of “Reduce” by the seven brokerages that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $15.00.

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. raised their price objective on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Citigroup decreased their target price on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a report on Friday, October 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Finally, Truist Financial reissued a “hold” rating and set a $13.00 price target (down previously from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd.

Insider Transactions at Integra LifeSciences

In related news, Director Jeffrey A. Graves purchased 9,000 shares of the company’s stock in a transaction dated Wednesday, November 5th. The shares were purchased at an average price of $11.35 per share, with a total value of $102,150.00. Following the acquisition, the director directly owned 41,086 shares in the company, valued at $466,326.10. The trade was a 28.05% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.54% of the company’s stock.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Integra LifeSciences in the first quarter worth $277,000. Goldman Sachs Group Inc. increased its position in Integra LifeSciences by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after acquiring an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock valued at $5,373,000 after acquiring an additional 45,693 shares during the period. Finally, Strs Ohio bought a new position in Integra LifeSciences in the first quarter valued at about $400,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $13.58 on Friday. The company has a 50 day simple moving average of $12.62 and a two-hundred day simple moving average of $13.44. Integra LifeSciences has a fifty-two week low of $10.87 and a fifty-two week high of $27.13. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -2.10 and a beta of 1.02. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.80 and a current ratio of 3.14.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.11. Integra LifeSciences had a positive return on equity of 14.06% and a negative net margin of 30.15%.The company had revenue of $402.06 million for the quarter, compared to the consensus estimate of $414.31 million. During the same quarter in the prior year, the business posted $0.41 EPS. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS and its FY 2025 guidance at 2.190-2.240 EPS. Analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.